Theraclone setback as BARDA says no to flu MAb
This article was originally published in Scrip
Theraclone Sciences, which announced a merger with PharmAthene recently, will not get Phase II of its lead monoclonal antibody candidate for serious flu paid for by BARDA. The Biomedical Advanced Research and Development Authority has decided not to use federal funds to bankroll the proposal, which Theraclone submitted in August.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.